These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 28840400)

  • 21. The use of long acting β₂-agonists, alone or in combination with inhaled corticosteroids, in chronic obstructive pulmonary disease (COPD): a risk-benefit analysis.
    Cave AC; Hurst MM
    Pharmacol Ther; 2011 May; 130(2):114-43. PubMed ID: 21276815
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Medical treatment of COPD].
    Vestbo J; Titlestad IL
    Ugeskr Laeger; 2013 Apr; 175(18):1261-4. PubMed ID: 23651802
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment trends in patients with asthma-COPD overlap syndrome in a COPD cohort: findings from a real-world survey.
    Ding B; Small M
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1753-1763. PubMed ID: 28670116
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacological basis and scientific rationale underlying the targeted use of inhaled corticosteroid/long-acting β2-adrenergic agonist combinations in chronic obstructive pulmonary disease treatment.
    Pelaia G; Muzzio CC; Vatrella A; Maselli R; Magnoni MS; Rizzi A
    Expert Opin Pharmacother; 2015; 16(13):2009-21. PubMed ID: 26194120
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is the use of beta-blockers in COPD still an unresolved dilemma?
    Foresi A; Cavigioli G; Signorelli G; Pozzoni MB; Olivieri D
    Respiration; 2010; 80(3):177-87. PubMed ID: 20639691
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of cardioselective beta-blockers on mortality in patients with chronic obstructive pulmonary disease and atherosclerosis.
    van Gestel YR; Hoeks SE; Sin DD; Welten GM; Schouten O; Witteveen HJ; Simsek C; Stam H; Mertens FW; Bax JJ; van Domburg RT; Poldermans D
    Am J Respir Crit Care Med; 2008 Oct; 178(7):695-700. PubMed ID: 18565952
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardio-selective and non-selective beta-blockers in chronic obstructive pulmonary disease: effects on bronchodilator response and exercise.
    Chang CL; Mills GD; McLachlan JD; Karalus NC; Hancox RJ
    Intern Med J; 2010 Mar; 40(3):193-200. PubMed ID: 19383058
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy.
    Mapel D; Laliberté F; Roberts MH; Sama SR; Sundaresan D; Pilon D; Lefebvre P; Duh MS; Patel J
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1825-1836. PubMed ID: 28684905
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Use of beta blockers in cardiovascular diseases and bronchial asthma/COPD].
    Glaab T; Weiss T
    Internist (Berl); 2004 Feb; 45(2):221-7. PubMed ID: 14991165
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhaled corticosteroids and mortality in COPD.
    Netzer G
    Chest; 2007 Mar; 131(3):939; author reply 940. PubMed ID: 17356119
    [No Abstract]   [Full Text] [Related]  

  • 31. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial.
    Singh D; Papi A; Corradi M; Pavlišová I; Montagna I; Francisco C; Cohuet G; Vezzoli S; Scuri M; Vestbo J
    Lancet; 2016 Sep; 388(10048):963-73. PubMed ID: 27598678
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of cardioselective β-blockers and overall death and cardiovascular outcomes in patients with COPD: a population-based cohort study.
    Dong YH; Chang CH; Wu LC; Lai MS
    Eur J Clin Pharmacol; 2016 Oct; 72(10):1265-1273. PubMed ID: 27444174
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD.
    Kardos P; Worsley S; Singh D; Román-Rodríguez M; Newby DE; Müllerová H
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2885-2895. PubMed ID: 27932872
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS.
    Latorre M; Novelli F; Vagaggini B; Braido F; Papi A; Sanduzzi A; Santus P; Scichilone N; Paggiaro P
    Pulm Pharmacol Ther; 2015 Feb; 30():44-50. PubMed ID: 25445928
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral Low-dose Theophylline on Top of Inhaled Fluticasone-Salmeterol Does Not Reduce Exacerbations in Patients With Severe COPD: A Pilot Clinical Trial.
    Cosío BG; Shafiek H; Iglesias A; Yanez A; Córdova R; Palou A; Rodriguez-Roisin R; Peces-Barba G; Pascual S; Gea J; Sibila O; Barnes PJ; Agusti A
    Chest; 2016 Jul; 150(1):123-30. PubMed ID: 27107490
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of beta-blocker use and selectivity with outcomes in patients with heart failure and chronic obstructive pulmonary disease (from OPTIMIZE-HF).
    Mentz RJ; Wojdyla D; Fiuzat M; Chiswell K; Fonarow GC; O'Connor CM
    Am J Cardiol; 2013 Feb; 111(4):582-7. PubMed ID: 23200803
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Comorbidity of Chronic Obstructive Pulmonary Disease and Cardiovascular Diseases: Place of Therapy with Modern β-Adrenoblockers].
    Belenkov YN; Tsvetkova OA; Privalova EV; An GV; Ilgisonis IS; Voronkova OO
    Kardiologiia; 2019 Jun; 59(6):48-55. PubMed ID: 31242841
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical inquiries. Do beta-blockers worsen respiratory status for patients with COPD?
    Baselli LM; Oswald MA; Nashelsky JM
    J Fam Pract; 2005 May; 54(5):472-3. PubMed ID: 15865911
    [No Abstract]   [Full Text] [Related]  

  • 39. Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases.
    Cazzola M; Calzetta L; Rinaldi B; Page C; Rosano G; Rogliani P; Matera MG
    Drugs; 2017 May; 77(7):721-732. PubMed ID: 28349353
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of ICS in COPD: From Blockbuster Medicine to Precision Medicine.
    Contoli M; Corsico AG; Santus P; Di Marco F; Braido F; Rogliani P; Calzetta L; Scichilone N
    COPD; 2017 Dec; 14(6):641-647. PubMed ID: 29116901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.